Abstract

We at MD Anderson Cancer Center are concerned by the suggestions made by Eloy et al[1][1] in the August 2009 issue of the American Journal of Neuroradiology regarding fluorodeoxyglucose (FDG) activity in the thyroid gland in patients undergoing positron-emission tomography (PET/CT) for nonthyroid

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.